- CDC respiratory virus updates: The CDC has a new webpage dedicated to “updates on the respiratory illness season.” So far, it just includes summaries of the agency’s two reports on new variant BA.2.86. Going forward, the page will be updated weekly with further information on COVID-19, flu, RSV, and other viruses spreading this fall and winter.
- Potential biomarker for Long COVID brain fog: A new paper, published this week in Nature by a coalition of researchers in the U.K., connects blood clot issues during acute COVID-19 to cognitive symptoms later on. The researchers found that some patients had low levels of two specific proteins connected to blood clots, based on blood samples taken early in their infections; the same patients were likely to experience brain fog and similar symptoms. If these results are replicated in other studies, the proteins could be used as biomarkers (i.e. medical indicators) of Long COVID symptoms, potentially a big step for research and treatments.
- Long COVID research presented at Keystone Symposia event: Speaking of Long COVID research: scientists gathered to discuss this condition at a conference last week in New Mexico. The conference was hosted by Keystone Symposia, an organization that convenes meetings on important life sciences topics. Highlights from the event included a presentation showing changes to muscle tissue during post-exertional malaise, along with presentations from the Patient-Led Research Collaborative, the National Institutes of Health, Resia Pretorius from Stellenbosch University in South Africa, Akiko Iwasaki from Yale University, and more. I look forward to seeing papers expanding on the talks that occurred at this meeting.
- COVID-19’s impact on Native Americans: Another notable paper from this week examined COVID-19’s disproportionate impacts on Native Americans in New Mexico. Researchers at the University of New Mexico Hospital analyzed patient outcomes in early pandemic waves, from spring 2020 through winter 2021. Compared to white and Hispanic patients, Native Americans were more likely to experience severe COVID-19 outcomes such as more time spent in the hospital and going on a ventilator. “Self-reported AI/AN race/ethnicity emerged as the highest risk factor for severe COVID-19,” the researchers reported, suggesting that this vulnerable group of people deserves additional safety resources.
- COVID-19 burden for cancer patients: One more study to highlight: researchers at Massachusetts General Hospital examined COVID-19 mortality among cancer patients during the first two years of the pandemic, using data from the CDC. People with cancer were more likely to die of COVID-19 during the winter Omicron wave in 2021-2022, compared to the surge during the prior winter (with 18% higher deaths). Meanwhile, deaths among the general population went down from the first to the second winters. Like the study above, this paper suggests that greater protections are needed for vulnerable people during times of high COVID-19 spread. (For example: we could keep masks in healthcare settings!)
Tag: Featured sources
-
Sources and updates, September 3
-
Sources and updates, August 20
- New toolkit for estimating COVID-19 risk from wastewater: Researchers at Mathematica published a new, open-source toolkit for interpreting wastewater data. It includes an algorithm that scientists and health officials can use to identify when a new surge might be starting based on wastewater results, as well as a risk estimator tool that combines wastewater data with healthcare metrics. The researchers developed this toolkit using data from North Carolina during the Delta and Omicron surges; their paper in PNAS last month describes it further, as does a blog post by the Rockefeller Foundation (which funded the project). This tool doesn’t provide real-time updates, as it only includes wastewater data through December 2022, but it offers a helpful model for using this source to inform public health policies.
- Vaccine delays for uninsured Americans: The CDC estimates that new COVID-19 boosters will become available in late September or early October, as I wrote last week. But Americans without health insurance may have to wait longer to get the shots or pay a hefty price tag, according to recent reporting from POLITICO. A federal government program with national pharmacy chains, which will provide the shots for free to uninsured people, is not slated to start until mid-October. Instead, uninsured people will need to pay out-of-pocket or find one of a small number of federal health centers to get vaccinated; this is likely to discourage vaccinations, POLITICO reports. And the number of uninsured people is only growing thanks to Medicaid redeterminations.
- Budget cuts at the CDC could mean layoffs: A recent op-ed in STAT News, written by two researchers familiar with the CDC’s organizational structure, warns that budget cuts at the agency could lead to a significant reduction in public health workers. The CDC’s budget was cut as part of the federal government’s debt ceiling negotiations last month, the authors explain. It faces a cut of about 10%, or $1.5 million a year, which could lead to significant layoffs. The reduced jobs are particularly likely to impact staff at the state and local levels, the op-ed’s authors argue, rather than at the CDC’d headquarters in Atlanta. “Reductions there will cut public health services and will have their greatest impact on the most vulnerable populations,” they write.
- Vaccine effectiveness for young children: Speaking of the CDC: the agency published a study this week in its Morbidity and Mortality Weekly Report describing COVID-19 vaccine effectiveness for the youngest children who are eligible (i.e. under five years old). Researchers at the CDC and partners at healthcare centers across the country tracked COVID-related emergency department and urgent care visits among young children, from July 2022 through July 2023. Effectiveness for the primary series was low: Moderna’s two-dose series scored just 29% effective at preventing ED and urgent care visits, while Pfizer’s three-dose series was 43% effective. Children who received a bivalent (Omicron-specific) follow-up dose were much more protected, however: this regimen was 80% effective. Bivalent boosers should be a priority for young kids along with adults, the study suggests.
- Immune system changes following COVID-19: Another notable study from this week, from scientists at Weill Cornell Medicine and other institutions, describes how severe COVID-19 cases may damage patients’ immune systems. The researchers analyzed how specific genes were expressed in immune system cells taken from people who had severe cases of COVID-19. They found expression changes as long as a year after patients’ initial infections, and connected those changes to inflammation, organ damage, and other long-term issues. These genetic changes may point to one cause for Long COVID symptoms, though the study is somewhat limited by its focus on patients who had severe symptoms early on (as most people with Long COVID have initially milder cases).
- Smell and taste loss following COVID-19: While smell loss has long been considered a classic COVID-19 symptom, a new study shows that taste loss is also common, even among people who don’t lose their sense of smell. Researchers at the Monell Chemical Senses Center (a nonprofit center in Philadelphia) studied these symptoms through an online survey, which included about 10,000 participants between June 2020 and March 2021. COVID-positive participants were more likely to report smell issues, taste issues, and both together, compared to people who didn’t get sick, the researchers found. Their survey methodology—which included asking people to self-assess their senses by smelling common household objects—could be used for further large-scale studies of these symptoms, the researchers write.
-
Sources and updates, August 13
- CDC identifies continued Long COVID risk: A new study from the CDC this week, published in the agency’s Morbidity and Mortality Weekly Report, summarizes data from the CDC and Census Household Pulse Survey examining Long COVID prevalence in the U.S. According to the survey, Long COVID prevalence declined slightly from summer 2022 to early 2023, but has remained consistent this year at about 6% of all U.S. adults. The survey also found that about one in four adults with Long COVID consistently report “significant activity limitations” from the condition, meaning they are less able to work and participate in other aspects of daily life. Treating Long COVID and supporting long-haulers should be priorities for the healthcare system, the study’s authors write.
- Mitochondrial dysfunction in Long COVID: Another new paper, published this week in Science Translational Medicine, demonstrates the role that mitochondria may play in Long COVID. Researchers at the Children’s Hospital of Philadelphia studied tissue samples from autopsies and animals infected with COVID-19, finding that the coronavirus led to malfunctioning mitochondria in several key organ systems. These malfunctions may contribute to Long COVID symptoms such as fatigue and brain fog, and could be a target for future treatments. Elizabeth Cooney at STAT News covered the study in more detail.
- Benefits of vaccination during pregnancy: One more notable new study: researchers at the National Institute of Allergy and Infectious Diseases (or NIAID, part of the NIH) tracked the impacts of COVID-19 vaccination for pregnant people. The study included 240 vaccinated participants who contributed blood samples, between July 2021 through January 2022. Both the parents and their newborns developed antibodies against the coronvirus following infection, the researchers found. While previous papers have demonstrated the value of vaccination for new parents, this study is one of the largest so far to show that protection is conferred to newborns.
- Wastewater surveillance webinar from the People’s CDC: If you’ve been following wastewater data to keep up with COVID-19 trends but have had questions about how this form of surveillance works, you may find it helpful to watch this recorded webinar from health advocacy organization the People’s CDC. In the video, Marc Johnson, a professor at the University of Missouri and director of the state’s wastewater surveillance program, talks through how wastewater is tested for the coronavirus (and variants), how to interpret wastewater data, cryptic lineages, and more. Understanding this novel data source is increasingly important now, as traditional healthcare data on COVID-19 are less reliable.
- New federal heat surveillance dashboard: Finally, in other public health news, the federal government has launched a new dashboard to track heat-related health issues. The dashboard compiles data from Emergency Medical Services reports across the country, representing responses to 911 calls for any health reason related to heat stress. (You can see the list of potential health events in the dashboard’s documentation.) Currently, many southern states are experiencing high levels of heat-related health problems, according to the dashboard. Many of the same states are also experiencing COVID-19 upticks right now—trends that may be related, as more people gather inside during hot weather.
-
Sources and updates, August 6
- Novavax vaccine safety: This week, the CDC published new data in its Morbidity and Mortality Weekly Report (MMWR) affirming the safety of Novavax’s COVID-19 vaccine. Unlike the Pfizer and Moderna vaccines (which use the virus’ genetic information), the Novavax vaccine works by inserting direct copies of the coronavirus spike protein into the body. It was authorized in summer 2022 as a primary series or booster for people who may be unable or unwilling to receive an mRNA vaccine. The CDC found that, among 70,000 Novavax vaccine doses administered between July 2022 and March 2023, no new safety concerns emerged.
- Insurance coverage for COVID-19 tests: Insurance companies have covered COVID-19 tests very unevenly since the federal health emergency ended this spring. But that could change, if an advisory panel called the U.S. Preventive Services Task Force recommends that the federal government require insurers to cover COVID-19 testing. The panel is exploring this option, reports Sarah Owermohle at STAT News, though it could face legal challenges.
- Breath test for COVID-19: A couple of weeks ago, I shared a new tool for detecting SARS-CoV-2 particles in the air, developed by researchers at Washington University in St. Louis. The same team has just published another paper, in ACS Sensors, about a similar tool that can diagnose a coronavirus infection using a patient’s breath. This breath test can detect the virus with as few as two breaths and in under 60 seconds, and is close in accuracy to a PCR test. The research team is working to continue testing this device and potentially manufacture it more broadly, according to a press release.
- COVID-19 spread among white-tailed deer: A recent paper in Nature Communications describes how SARS-CoV-2 has circulated widely among white-tailed deer across the U.S. The research team (which includes scienitsts at the CDC, U.S. Department of Agriculture, and the University of Missouri) collected about 9,000 respiratory samples from deer in 26 states and Washington D.C. between fall 2021 and spring 2022. Hundreds of the samples were positive for SARS-CoV-2, leading the team to study genetic sequences and study how the virus had evolved in this population. The team’s full data are available online. (H/t Data Is Plural.)
-
Sources and updates, July 30
- New papers show wastewater’s predictive value: This week, I noted three recently-published papers that all demonstrate wastewater surveillance’s value for flagging changes in COVID-19 trends before other metrics, such as hospitalizations. One paper, in Nature, found that wastewater trends preempted hospitalization trends by one to four weeks, in 150 U.S. counties. Another paper, in JAMA Network Open, found that wastewater trends tracked with case trends in 268 U.S. counties from January through September 2022; however, the correlation became weaker with reduced clinical testing over time. And a third paper, in PNAS, shares an algorithm that can flag community-level COVID-19 surges before they show up in other metrics, using data from North Carolina’s wastewater surveillance.
- Long COVID’s impact on employment: The Urban Institute, a think tank focused on economic and social policy research, published a report exploring employment challenges and related hardships among people with Long COVID. The researchers (a group that included Lisa McCorkell from the Patient-Led Research Collaborative) analyzed results from Long COVID questions included in an Urban Institute survey, conducted among more than 7,500 American adults across the country in December 2022. Among the findings: 10% of adults with Long COVID stopped working for a period due to their symptoms while another 5% reduced their work hours; 24% limited activities outside of work; 42% reported food insecurity in the last year; 20% reported difficulty paying their rent or mortgage.
- Characterizing potential Long COVID phenotypes: Another Long COVID study from this week, published in The Lancet: a research consortium including several medical centers across Europe tracked patients over time, seeking to better understand different subtypes of the condition. The study included about 1,000 people with at least one Long COVID symptom, tracked over one year from their initial COVID-19 diagnosis. Researchers found four potential subtypes: one similar to ME/CFS (including fatigue and cognitive symptoms), one with respiratory symptoms, one with chronic pain, and one with changes to taste and smell. The researchers also noted some patient characteristics and aspects of acute illness that may contribute to increased risk of different subtypes.
- Outdoor transmission at a night market: One more notable new paper: researchers at local health agencies in China’s Zhejiang province reported on coronavirus transmission at an outdoor night market, in Frontiers in Public Health. In one day at the night market, three infected visitors led to 131 secondary cases, the researchers found. Based on samples from both people at the market and surfaces, the researchers estimated that particles of an Omicron BA.5 strain could linger for over an hour and still be contagious. The study suggests that, even in outdoor settings, transmission is still possible when other precautions aren’t taken.
- Acute Hospital at Home data: The Data Liberation Project, which collects and shares data from public records requests, recently published a dataset from a COVID-era program by the Centers for Medicare and Medicaid Services (CMS) which allowed hospitals to treat patients in their homes. Early this year, the project filed a FOIA request for data indicating which hospitals applied to participate in the program and how their patients fared. CMS completed the request in June, and DLP is working to process and understand the resulting data. If you’re interested in using the data, you can check out the documentation and sign up for updates.
- Diagnosis challenges with alpha-gal syndrome: Finally, a bit of non-COVID public health news: the CDC recently released some data showing challenges with diagnosing alpha-gal syndrome—a disease transmitted by tick bites that leads to new allergies—despite recent increases in its spread. The CDC estimates that up to 450,000 people in the U.S. may have been impacted by this disease, potentially developing new allergies to meat and other animal products. Yet in one CDC study, the majority of health providers surveyed were not confident in their ability to diagnose the syndrome. This trend reflects similar challenges for other chronic diseases that might be new or unfamiliar to providers, such as Long COVID.
-
Sources and updates, July 23
- Grants to help with global pandemic preparedness: This week, the World Bank’s Pandemic Fund announced the recipients of its first round of grants. The fund is a finance initiative to “strengthen pandemic prevention, preparedness, and response capacities,” particularly for low- and middle-income countries. Its first round of grants will go to 37 countries across 6 global regions, distributing $338 million in funding. The full list of awards is available on the World Bank’s website.
- Genetic marker of asymptomatic COVID-19: A new paper published in Nature this week reports on a common genetic marker that may lead people to have symptom-free COVID-19 cases. The researchers (a team from the University of California San Francisco and other institutions) searched for genetic patterns among 30,000 people who shared their COVID-19 symptom information through a smartphone app. They found a correlation between asymptomatic infection and a specific version of a gene related to T cells. As Eric Topol notes in his newsletter, this study follows two others that examined genetic markers of Long COVID.
- Quantifying cognitive symptoms of Long COVID: Speaking of Long COVID: researchers at Kings College London studied the condition’s cognitive symptoms (also called brain fog) by measuring patients’ performance in different mental tasks. The study included over 3,000 participants, more than half of whom completed two rounds of testing over two years. Overall, the researchers found that cognitive symptoms persisted for nearly two years after patients’ initial infections, and most severe for patients with the longest-lasting Long COVID impacts. For these patients, “the effect of COVID-19 on test accuracy was comparable in size to the effect of a 10-year increase in age,” per a press release by Kings College London.
- Long COVID is common in children: Another Long COVID study published this week: researchers at a hospital in Toronto compiled a review paper examining the condition’s prevalence among children. Their review included 30 studies including about 15,000 total pediatric patients. Across all the studies, researchers reported that about 16% of children experienced at least one Long COVID symptom three or more months after their COVID-19 infections. However, compiling these data was a challenging task because different studies used different definitions of Long COVID, different methods of following up with patients over time, and other inconsistencies, the authors wrote.
- Dogs detecting COVID-19 through scent: One more paper that stuck out to me this week: a pair of researchers (one at the University of California, Santa Barbara and one at a biotech company focused on sniffing for COVID-19) examined how well dogs can detect the coronavirus. This was also a review paper, including 29 studies and 31,000 COVID-19 test samples. Overall, the dogs performed with similar accuracy to PCR tests, researchers found. “We believe that scent dogs deserve their place as a serious diagnostic methodology that could be particularly useful during pandemics,” one of the authors said in a statement.
- Monoclonal antibody to protect babies from RSV: Finally, a bit of good news for combatting another common respiratory virus: the FDA has approved a new monoclonal antibody treatment to protect infants and young children against RSV. The therapy is likely to be recommended by the CDC and manufactured in time for respiratory virus season this fall. In clinical trials, it lowered the risk of an RSV infection requiring medical care by about 76%—which is a big deal for a disease that leads to more babies in hospitals than any other in the U.S., reports Helen Branswell at STAT.
-
Sources & updates, June 25
- Commonwealth Fund releases 2023 state health scorecard: This week, health research organization the Commonwealth Fund published its 2023 rankings of state health systems. These rankings are an extensive data source for anyone seeking to better understand the decentralized health system in the U.S., and may be particularly useful for local reporters looking for data on how their state compares to others. In the 2023 rankings, the researchers have added new metrics related to care and health outcomes for women, mothers, and infants. This year’s data also highlight preventable deaths from COVID-19 and other causes, and state efforts to take people off of Medicaid following the pandemic emergency’s end.
- New advisory about Long COVID and mental health: The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA), a federal health agency under the overall Department of Health and Human Services (HHS), published a detailed advisory explaining the mental health implications of Long COVID. This advisory is directed at primary care doctors who may be seeing Long COVID among their patients, as well as others in the medical community who may benefit from the information. SAMHSA highlights that mental health symptoms may result from a coronavirus infection itself as well as from the stress and social isolation that long-haulers experience. For more on this topic, check out this article I wrote last year.
- Rapid test accuracy can vary widely: A common question that I’ve received from readers in the last few months has been, “How accurate are rapid tests with newer variants?” A new study, published last week in the journal Microbiology Spectrum, offers some insight. The researchers (a team at CalTech) found that rapid tests still work to detect the coronavirus, but their accuracy varies based on viral load and specimen type. Tests that involved swabbing the patient’s throat (along with their nose) were significantly more accurate than nose swabs alone. Tests conducted later in the course of a patients’ infection, when they had higher viral loads, were also more accurate, though some patients never tested positive on rapid tests despite testing positive on PCR. My takeaway here: swabbing your throat and testing multiple times help improve accuracy, but the best option is always to get a PCR if you can.
- CDC and state agencies track reinfections: Another new study, published this week in the CDC’s Morbidity and Mortality Weekly Report, examines coronavirus reinfections in the era of Omicron. Researchers at the CDC and 18 state and local health departments collaborated to track reinfections from September 2021 through December 2022, finding that these infections went up significantly when Omicron arrived in late 2021. The median time between infections ranged from 269 to 411 days, the researchers found, suggesting that Americans may expect to be sick with COVID-19 once or twice a year while our Omicron baseline persists.
- COVID-19 risk and air pollution exposure: One more study I wanted to highlight this week: researchers at Hasselt University in Belgium tracked the air pollution exposures of about 330 COVID-19 patients at hospitals in Belgium. Patients who were exposed to worse air pollution prior to their admission experienced more severe COVID-19 outcomes, including longer hospitalization and admission to the ICU. This paper provides further confirmation that poor air quality and COVID-19 can be compounding health problems for many people.
- Data problems persist with non-COVID vaccines: The CDC’s vaccine advisory committee met this week to discuss two new RSV vaccine candidates, recently approved by the FDA for seniors. While the CDC committee did vote to recommend these vaccines, I was struck by discussion (in Helen Branswell’s coverage for STAT) that the experts said they did not have sufficient data to make a truly informed decision. I’ve written a lot about data issues for COVID-19 vaccines; the same decentralized health system problems that make it hard to track COVID-19 vaccine effectiveness also apply to products for other diseases.
-
Sources and updates, June 18
- New York Times COVID-19 tracker is back: After shutting down ahead of the ending federal public health emergency, the New York Times COVID-19 tracker has now resumed updates. Since the tracker is based on CDC data, case numbers and other major metrics are no longer available; but readers can find hospital admissions, deaths, and vaccinations nationally and by state, along with some local data based on hospital service areas. The NYT website doesn’t give much information about why they resumed updates—if anyone reading this can share what happened, please let me know! (And thank you to reader Robin Lloyd who flagged the renewed updates.)
- CDC Director calls for more data authority: CDC Director Rochelle Walensky appeared in front of Congress this week, speaking to Republican lawmakers for a hearing about her time leading the agency before she steps down at the end of June. One notable trend from the hearing, according to reporting by Rachel Cohrs at STAT News: Walensky acknowledged that the CDC wasn’t able to collect some key COVID-19 data points, such as vaccination rates for COVID-19 patients in hospitals. Walensky called for Congress to give the CDC more authority in collecting data from state and local health departments.
- CDC expanding its wastewater testing targets: Another CDC update for this week: the agency’s National Wastewater Surveillance System is expanding the pathogens that it will look for in sewage, Genome Web reports. NWSS plans to test for several respiratory viruses (COVID-19, flu, RSV), foodborne infections such as E. coli and norovirus, antimicrobial resistance genes, mpox, and other pathogens that may warrant concern. CDC scientists are working with the company GT Molecular to develop and test new assays. Other wastewater research groups are similarly developing tests to expand the health data that we get from sewage, I’ve learned in reporting for an upcoming story (which will be out later this summer).
- Genomic surveillance to keep tabs on Omicron’s evolution: CDC researchers invovled with tracking coronavirus variants shared some updates in a study published this week by the agency’s Morbidity and Mortality Weekly Report. As fewer people are getting PCR tests across the U.S., the CDC has access to fewer samples for sequencing than it did at prior points in the pandemic. As a result, scientists have had to update their analytical procedures for using available data to estimate how much different variants are spreading. According to the CDC, Omicron has dominated the U.S. since early 2022, with earlier BA lineages giving way to XBB.
- Fungal infections increased during the pandemic: In recent years, hospital patients have become increasingly at risk of infection with fungi, which can spread widely in healthcare settings. A new paper from the CDC adds evidence to this trend: fungal infections in hospitals have increased steadily from 2019 through 2021, the researchers found. The researchers also found that patients hospitalized with COVID-19 and a fungal infection had high mortality rates, with almost half of these patients dying in 2020-2021. COVID-19 can disrupt patients’ immune systems and make them more vulnerable to fungi, the researchers suggested. This is a major threat that’s likely to continue in coming years.
-
Sources and updates, June 11
- Quantifying Long COVID’s impact on day-to-day life: A new study published this week in the BMJ is one of the first I’ve seen to focus not on Long COVID’s symptoms, but on how it impacts quality of life for patients. Researchers at University College London assessed life impacts for about 3,700 Long COVID patients using surveys in an online health platform. The surveys found that “Long COVID can leave people with worse fatigue and quality of life than some cancers, yet the support and understanding is not at the same level,” study coauthor Dr. William Henley said in a statement about the research. This study confirms what I’ve heard from many long-haulers in interviews over the last couple of years.
- Long COVID and ME/CFS similarities: Another notable Long COVID paper: two leading experts on chronic illness, Dr. Anthony Komaroff at Harvard Medical School and W. Ian Lipkin at Columbia University, wrote a detailed review identifying commonalities between Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a debilitating condition with symptoms similar to Long COVID that often occurs after infection. ME/CFS has long been under-recognized and understudied, but there are still lessons from this condition that can inform Long COVID research and lead to answers for both diseases. The review paper points to directions for future study.
- Metformin for Long COVID: One more Long COVID paper: a study published this week in The Lancet shares results from a Long COVID clinical trial at the University of Minnesota, which found that the diabetes drug metformin reduces the risk of developing long-term symptoms when patients take it early in the course of a COVID-19 case. I shared this study when it was first posted as a preprint in March, and also spoke to one of its authors for my STAT/MuckRock story about the RECOVER initiative. I’m glad to see that the major findings haven’t changed in this peer-reviewed version; metformin appears to be a promising treatment option, though more study is needed.
- At-home test receives FDA approval: This week, the FDA approved an at-home, rapid COVID-19 test made by the company Cue Health. It’s the first at-home test to receive full approval, as these tests have previously received Emergency Use Authorization under public health emergency rules. With the federal emergency over, the FDA is encouraging test companies to apply for full approval so that at-home COVID-19 tests can be distributed (and marketed) like other commonly-available health products. The emerency authorizations still apply for tests that don’t have full approval yet, though.
- COVID-19 Medicaid rules led to more coverage for children: For the first three years of the pandemic, federal rules tied to the public health emergency forbid states from kicking their residents off of Medicaid. The policy led to a significant increase in Americans with health insurance—and that includes children, according to a new paper published this week in Health Affairs. For states that changed their Medicaid rules for children due to the pandemic policy, coverage increased by about 5% from 2019 to 2021, representing thousands of kids who were able to get healthcare more easily. Of course, these kids and their family members are now likely to lose their health insurance, as the federal policy ended in April.
- Animal behaviors changed during 2020 lockdowns: Remember when, in the early days of the pandemic, big cities with more stringent lockdowns saw more wild animals than normal? A new paper from a large coalition of scientists, published this week in Science, finds that this pattern wasn’t just anecdotal: animal behavior really did change. The scientists compiled a large dataset of animals tracked with GPS, representing 2,300 individuals from 43 different mammal species, and compared their behaviors in spring 2020 to the same period in 2019. Animals living in areas under strict lockdowns were more likely to travel outside their normal ranges, the researchers found.
COVID-19 Data Dispatch 